Passive infusion of an S2-Stem broadly neutralizing antibody protects against SARS-CoV-2 infection and lower airway inflammation in rhesus macaques
Authors:
Open Access
- 23 January 2025
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS Pathogens
- Vol. 21 (1) , e1012456
Abstract
The continued evolution of SARS-CoV-2 variants capable of subverting vaccine and infection-induced immunity suggests the advantage of a broadly protective vaccine against betacoronaviruses (β-CoVs). Recent studies have isolated monoclonal antibodies (mAbs) from SARS-CoV-2 recovered-vaccinated donors capable of neutralizing many variants of SARS-CoV-2 and other β-CoVs. Many of these mAbs target the conserved S2 stem region of the SARS-CoV-2 spike protein, rather than the receptor binding domain contained within S1 primarily targeted by current SARS-CoV-2 vaccines. One of these S2-directed mAbs, CC40.8, has demonstrated protective efficacy in small animal models against SARS-CoV-2 challenge. As the next step in the pre-clinical testing of S2-directed antibodies as a strategy to protect from SARS-CoV-2 infection, we evaluated the in vivo efficacy of CC40.8 in a clinically relevant non-human primate model by conducting passive antibody transfer to rhesus macaques (RM) followed by SARS-CoV-2 challenge. CC40.8 mAb was intravenously infused at 10mg/kg, 1mg/kg, or 0.1 mg/kg into groups (n = 6) of RM, alongside one group that received a control antibody (PGT121). Viral loads in the lower airway were significantly reduced in animals receiving higher doses of CC40.8. We observed a significant reduction in inflammatory cytokines and macrophages within the lower airway of animals infused with 10mg/kg and 1mg/kg doses of CC40.8. Viral genome sequencing demonstrated a lack of escape mutations in the CC40.8 epitope. Collectively, these data demonstrate the protective efficiency of broadly neutralizing S2-targeting antibodies against SARS-CoV-2 infection within the lower airway while providing critical preclinical work necessary for the development of pan–β-CoV vaccines.Keywords
Funding Information
- Bill and Melinda Gates Foundation (INV004923)
- Division of Intramural Research (UM1AI44462)
- Division of Intramural Research (R01AI170928)
- Division of Intramural Research (OD011132)
- Division of Intramural Research (OD026799)
This publication has 113 references indexed in Scilit:
- Serum and Salivary IgG and IgA Response After COVID-19 Messenger RNA VaccinationJAMA Network Open, 2024
- Durability of Vaccine-Induced and Natural Immunity Against COVID-19: A Narrative ReviewInfectious Diseases and Therapy, 2023
- Transmission and Infectious SARS-CoV-2 Shedding Kinetics in Vaccinated and Unvaccinated IndividualsJAMA Network Open, 2022
- Association of COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection by Time Since Vaccination and Delta Variant PredominanceJAMA, 2022
- Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19JAMA, 2021
- SARS-CoV-2 Viral Variants—Tackling a Moving TargetJAMA, 2021
- Baricitinib treatment resolves lower-airway macrophage inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaquesCell, 2021
- Vascular Disease and Thrombosis in SARS-CoV-2-Infected Rhesus MacaquesCell, 2020
- SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across TissuesCell, 2020
- Structure, Function, and Antigenicity of the SARS-CoV-2 Spike GlycoproteinCell, 2020